| 0 (0%) | 12-08 14:49 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 53.73 | 1-year : | 62.76 |
| Resists | First : | 46 | Second : | 53.73 |
| Pivot price | 43.09  |
|||
| Supports | First : | 39.7 | Second : | 35.79 |
| MAs | MA(5) : | 42.98 |
MA(20) : | 42.18 |
| MA(100) : | 35.51 |
MA(250) : | 0 | |
| MACD | MACD : | 0.7 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 70.2 |
D(3) : | 70.3 |
| RSI | RSI(14): 52.2 |
|||
| 52-week | High : | 46 | Low : | 14.8 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CGON ] has closed above bottom band by 47.1%. Bollinger Bands are 15.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 46.06 - 46.32 | 46.32 - 46.56 |
| Low: | 42.35 - 42.63 | 42.63 - 42.87 |
| Close: | 42.9 - 43.35 | 43.35 - 43.74 |
Mon, 08 Dec 2025
CG Oncology (CGON) Valuation Check After Strong Late-Breaking Cretostimogene Bladder Cancer Trial Results - simplywall.st
Sat, 06 Dec 2025
CG Oncology (NASDAQ:CGON) Sets New 1-Year High - Still a Buy? - MarketBeat
Fri, 05 Dec 2025
Cg Oncology Inc. (CGON) Live Share Price, Invest From India - INDmoney
Fri, 05 Dec 2025
Schroder Investment Management Group Acquires 155,737 Shares of CG Oncology, Inc. $CGON - MarketBeat
Wed, 26 Nov 2025
CG Oncology (NASDAQ: CGON) names Rossi to board amid BLA initiation - Stock Titan
Tue, 25 Nov 2025
CG Oncology (NASDAQ: CGON) highlights BOND-003 and CORE-008 NMIBC data at SUO meeting - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | -78 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 8.067e+007 (%) |
| Held by Institutions | 6.544e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.1289e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.05 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 68.9 % |
| Return on Equity (ttm) | -17.6 % |
| Qtrly Rev. Growth | 2.17e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.7953e+008 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -20.95 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 1.321e+007 |
| Forward Dividend | 1.222e+007 |
| Dividend Yield | 30764600% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|